Roche purchases the US rights to the drug Roivant for bowel disease.

Published Date: 28 Oct 2023

In an effort to offset declining sales in oncology, Swiss company Roche has agreed to pay Roivant and Pfizer an initial $7.11 billion for the rights to a new medication for inflammatory bowel disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How access to specialized cancer centers affects glioblastoma outcomes

2.

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

3.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

4.

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

5.

Beyond What Is Visible in Myelofibrosis?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot